Approved for use through 10/31/2002. OMB 0651-0031

	U.S. Patent and	mademark Office, O.	O. DEPARTMENT C	AL COMMENCE
Under the Paperwork Reduction Act of 1995, no persons are required	to respond to a colle	ction of information unles	s it contains a valid OM	B control numbe

Substitute for form 1449A/PTO					Complete if Known
				Application Number	10/551,998
INFO	RMATION	DIS	CLOSURE	Filing Date	October 5, 2006
STATEMENT BY APPLICANT				First Named Inventor	Kai SCHIEMANN, et al.
				Group Art Unit	1626
	(use as many she	ets as	necessary)	Examiner Name	CHU, Yong Liang
Sheet	1	of	2	Attorney Docket Number	MERCK-3073

	U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.1	U.S. Patent Doci Number	ıment Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY		
			37.0000				

***************************************	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Foreign Patent Docum Number <sup>a</sup>	ent Kind Code <sup>s</sup> ( <i>if known</i> )	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/Y.C./	B1	wo	01/29008	1 43	ARENA PHARMACEUTICALS INC.	04-26-2001	1	
/Y.C./	B2	wo	96/33175	A	SEARLE & CO	10-24-1996		
**	B3	DE	21-41-125	А	BYK-GULDEN LOMBERG GMBH			*****
/Y.C./	B4	wo	03/099793	A	TAKEDA LTD	12-04-2003		
/Y.C./	B5	wo	2004/024705	Α	TAKEDA LTD.	03-25-2004		
/Y.C./	B6	wo	2004/037248	A	CAREX SA	05-06-2004		
* *	~~~B7~~	DE	2201889	X	Merck Patent GribH	7-19-1973		
	B8	<i>~~</i> ₽ <u>@</u> ~~	<u>5</u> 2568033		Merck-Patent-EmbH	05 <u>-86-197</u> 4		,
**	B9	DE	2906252	A	Merck Patent GmbH	08-28-1980		

Examiner Signature	/Yong Ghu/	Date Considered	07/30/2008	]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents, <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/551,998	
INFORMATION DISCLOSURE				Filing Date	October 5, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Kai SCHIEMANN, et al.	
				Group Art Unit	1626	
(1	use as many si	heets as nec	essary)	Examiner Name	CHU, Yong Liang	···
Sheet	2	of	2	Attorney Docket Number	MERCK-3073	

Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ,
/Y.C./	C1	TAKEHITO OCHI ET AL.: "FR143166 ATTENUATES SPINAL PAIN TRANSMISSION THROUGH ACTIVATION OF THE SEROTONIG SYSTEM" EUROPEAN JOURNAL OF PHARMACOLOGY, Bd. 452, 2002, Pages 319-324, XP002284473, The Entire Document.	
/Y.C	/ C2	YOSHIKO SUZUKI ET AL; "IN VITRO AND IN VIVO PHARMACOLOGICAL PROFILE OF 4-(4-FLUOROBENZYLIDENE)-1-{2-'5-(4-FLUOROP HENYL)-1H-PYRAZOL-4-YL!ETHYL} PIPERIDINE (NRA0161)" LIFE SCIENCES, Bd. 71, 2002, pages 2603-2615, XP002284474, The Entire Document.	
/Y.C./	С3	KATRITZKY ET AL: "1,3-DIPOLAR CYCLOADDITIONS OF ELECTRON-RICH BENZOTRIAZOL-1- YLPROPENES" J. HETEROCYCLIC CHEM., Bd. 33, 1996, Pages 1637-1646, XP002284475, Figure 28, Pages 1640.	
/Y.C./	C4	PEREZ ET AL: "AN EASY METHOD FOR THE N-ALKYLATION OF AMIDES, CARBAMATES, UREAS AND AZOLES" HETEROCYCLES, Bd. 60, Nr. 1, 25 November 2002, Pages 167-175, XP002284476, Figures 10,11 and 12, Pages 168 and 173.	
/Y.C./	C5	O'BRIAN ET AL: "SOME REACTIONS OF 3-HYDROXY-1-PHENYLPYRAZOLE" J. ORG. CHEM., Bd.31, 1966, Pages 1538-1542, XP002284477, The Entire Document.	e d'e de conseile de la conseile de
/Y.C./	C6	DATABASE CHEMABS 'ONLINE! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1960, GRANDBERG, I.I. ET AL: "PYRAZOLES. XII. HYDROXY-AND CHLOROMETHYLATION OF 1-SUBSTITUTED PYRAZOLES" XP002284480, FOUND IN STN, DATABASE ACCESSION NO. 1961:99421, SUMMARY & ZHURNAL OBSHCHEI KHIMII, 30, 3324-8; CODEN: ZOKHA4; ISSN: 0044-460X, 1960.	*****
/Y.C.	C7	DATABASE BEILSTEIN; BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 29 NOVEMBER 1988; XP002284481, DATABASE ACCESSION NO. BRN 1127514 CAS-RN; 35000-58-9/ SUMMARY & DORN ET AL: J. PRAKT. CHEM., Bd. 313, 1971, Pages 236-246.	
/Y.C./	C8	BEBERNITZ ET AL.: "THE EFFECT OF 1,3-DIARYL-'1HI-PYRAZOL-4-ACETAMIDES ON GLUCOSE UTILIZATION IN OB/OB MICE" J. MED. CHEM., Bd. 44, Nr. 16, 2001, PAGES 2601-2611, XP002284478; SCHEMA 1, METHODE A, STRUKTUREN 2-5, REAKTIONEN A AND B.	
/Y.C./	С9	ECHEVARRIA ET AL: RESEARCH IN THE AZOLE SERIES. 102 '1!. SYNTHESIS AND 13C NMR STUDY OF PYRAZOLE-4-CARBOXALDEHYDES: J. HETEROCYCLIC CHEM., Bd. 30, 1993, PAGES 957-960, XP002284479, FORMULA 19, PAGE 957.	***************************************
/Y.C.	C10	DATABASE BEILSTEIN, BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 24 JANUARY 2002, XP002284482, DATABASE ACCESSION NO. BRN 8913586 & BRATENKO ET AL: RUSS. J. ORG. CHEM. EN, Bd. 37, Nr. 4, 2001, PAGES 552-555.	
/Y.C	C11	Abstract of Bratenko Et Al; XP002284482.	

Signature /Yong Chu/ Considered 07/30/2008	[Signature	/Yong Chu/	Date Considered	07/30/2008
--	------------	------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.